{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:13:18Z","timestamp":1784549598981,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.lungcan.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T20:05:07Z","timestamp":1646769907000},"page":"74-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy"],"prefix":"10.1016","volume":"168","author":[{"given":"Anna","family":"Minchom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Backenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archan","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2022.03.005_b0005","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"216","key":"10.1016\/j.lungcan.2022.03.005_b0010","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"36","key":"10.1016\/j.lungcan.2022.03.005_b0015","doi-asserted-by":"crossref","first-page":"38789","DOI":"10.18632\/oncotarget.5887","article-title":"In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer","volume":"6","author":"Hirano","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lungcan.2022.03.005_b0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"30","key":"10.1016\/j.lungcan.2022.03.005_b0025","article-title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","volume":"2019","author":"Kim","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.005_b0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2022.03.005_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2022.03.005_b0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.03.005_b0045","first-page":"1","article-title":"Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis","volume":"10","author":"Kate","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"issue":"6","key":"10.1016\/j.lungcan.2022.03.005_b0050","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.03.005_b0055","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2022.03.005_b0065","doi-asserted-by":"crossref","first-page":"232021","DOI":"10.1051\/bmdcn\/2017070423","article-title":"A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer","volume":"7","author":"Huang","year":"2017","journal-title":"Biomedicine (Taipei)"},{"issue":"3.5","key":"10.1016\/j.lungcan.2022.03.005_b0070","doi-asserted-by":"crossref","first-page":"HSR19-084","DOI":"10.6004\/jnccn.2018.7200","article-title":"Real-world treatment patterns and clinical outcomes in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations","volume":"17","author":"DerSarkissian","year":"2019","journal-title":"J. Natl. Compr. Cancer Network"},{"issue":"3.5","key":"10.1016\/j.lungcan.2022.03.005_b0075","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2018.7199","article-title":"Epidemiological findings and outcomes in non-small cell lung cancer patients with Exon 20 insertion mutations: A meta-analysis","volume":"17","author":"Crossland","year":"2021","journal-title":"J. Natl. Compr Cancer Network"},{"issue":"10","key":"10.1016\/j.lungcan.2022.03.005_b0080","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-20-4650","article-title":"Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR Exon 20 insertions","volume":"27","author":"Choudhury","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2022.03.005_b0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2022.03.005_b0090","doi-asserted-by":"crossref","first-page":"e0247620","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One."},{"issue":"13","key":"10.1016\/j.lungcan.2022.03.005_b0095","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A Novel bispecific antibody targeting EGFR and cMet Is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2022.03.005_b0100","unstructured":"RYBREVANT\u2122 (amivantamab-vmjw) [package insert], Horsham, PA: Janssen Biotech, Inc.; 2021 (https:\/\/www.rybrevant.com). Accessed June 21, 2021."},{"key":"10.1016\/j.lungcan.2022.03.005_b0105","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"2021","author":"Neijssen","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.lungcan.2022.03.005_b0110","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2022.03.005_b0115","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR Exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.lungcan.2022.03.005_b0120","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/19420862.2016.1249079","article-title":"Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells","volume":"9","author":"Grugan","year":"2017","journal-title":"MAbs"},{"issue":"Supplement 8","key":"10.1016\/j.lungcan.2022.03.005_b0125","doi-asserted-by":"crossref","first-page":"viii542","DOI":"10.1093\/annonc\/mdy292.118","article-title":"NJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase 1 results","volume":"29","author":"Cho","year":"2018","journal-title":"Ann. Oncol."},{"issue":"Supplement 4","key":"10.1016\/j.lungcan.2022.03.005_b0130","first-page":"S754","article-title":"Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC","volume":"31","author":"Cho","year":"2020","journal-title":"Ann. Oncol."},{"issue":"15Suppl","key":"10.1016\/j.lungcan.2022.03.005_b0135","first-page":"9009-9009","article-title":"JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC)","volume":"37","author":"Haura","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.lungcan.2022.03.005_b0140","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase 1 study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2022.03.005_b0145","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.03.005_b0150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/EDE.0000000000001267","article-title":"Single-arm trials with historical controls: Study designs to avoid time-related biases","volume":"32","author":"Suissa","year":"2021","journal-title":"Epidemiology"},{"key":"10.1016\/j.lungcan.2022.03.005_b0155","series-title":"Extending the Cox Model. Technical Report Series No. 58. Mayo Clinic, Rochester, MN","author":"Therneau","year":"1996"},{"issue":"28","key":"10.1016\/j.lungcan.2022.03.005_b0160","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2022.03.005_b0165","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12350-017-1012-y","article-title":"Reducing bias using propensity score matching","volume":"25","author":"Morgan","year":"2018","journal-title":"J. Nucl. Cardiol."},{"issue":"2","key":"10.1016\/j.lungcan.2022.03.005_b0170","first-page":"1","article-title":"The R package geepack for generalized estimating equations","volume":"15","author":"Hojsgaard","year":"2006","journal-title":"J. Stat. Soft"},{"issue":"19","key":"10.1016\/j.lungcan.2022.03.005_b0175","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/jnci\/djt211","article-title":"Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival","volume":"105","author":"Chubak","year":"2013","journal-title":"J. Natl. Cancer. Inst."},{"issue":"3","key":"10.1016\/j.lungcan.2022.03.005_b0180","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.jtho.2021.01.228","article-title":"Comparative clinical outcomes for patients with NSCLC harboring EGFR Exon 20 insertion mutations and common EGFR mutations","volume":"16","author":"Girard","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2022.03.005_b0185","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1200\/JCO.2020.38.15_suppl.9580","article-title":"Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions","volume":"38","author":"Horn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.03.005_b0190","doi-asserted-by":"crossref","first-page":"102105","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"5","key":"10.1016\/j.lungcan.2022.03.005_b0195","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1016\/j.cllc.2018.05.014","article-title":"Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials","volume":"19","author":"Kawachi","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2022.03.005_b0200","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1023\/A:1008399831512","article-title":"Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole","volume":"10","author":"Cottin","year":"1999","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222003749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:00:52Z","timestamp":1759237252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222003749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"alternative-id":["S0169500222003749"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Janssen Research and Development LLC. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}